Press Releases January 20, 2026: MaaT Pharma Announces First Patient Randomized in IMMUNOLIFE Phase 2 Study Sponsored by Gustave Roussy, To Explore the Role of the Gut Microbiome To Overcome ICI Resistance in Advanced NSCLC Patients with Antibiotic-Induced Dysbiosis MaaT Pharma Announces First Patient Randomized in IMMUNOLIFE Phase 2 Study Sponsored by Gustave Roussy,…MaaT PharmaJanuary 20, 2026
Press Releases November 5, 2025: MaaT Pharma Presents Updated Preclinical Data at SITC Annual Meeting Demonstrating Immune Activation and Anti-Tumor Activity of MaaT034 MaaT Pharma Presents Updated Preclinical Data at SITC Annual Meeting Demonstrating Immune Activation and Anti-Tumor…MaaT PharmaNovember 5, 2025
